Evidence map›Paper›PMID 25711385›Full record

ArticleJournal of neuroscience research2015

Cyclin-Dependent kinase 5 targeting prevents β-Amyloid aggregation involving glycogen synthase kinase 3β and phosphatases.

John Fredy Castro-Alvarez, Alejandro Uribe-Arias, Gloria Patricia Cardona-Gómez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroscience research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. CDK5 downregulation enhances synaptic plasticity.Cellular and molecular life sciences : CMLS · 2017
    Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

John Fredy Castro-AlvarezCellular and Molecular Neurobiology Area, Neuroscience Group of Antioquia, Faculty of Medicine, SIU, University of Antioquia, Medellín, Colombia.
Alejandro Uribe-AriasCellular and Molecular Neurobiology Area, Neuroscience Group of Antioquia, Faculty of Medicine, SIU, University of Antioquia, Medellín, Colombia.
Gloria Patricia Cardona-GómezCellular and Molecular Neurobiology Area, Neuroscience Group of Antioquia, Faculty of Medicine, SIU, University of Antioquia, Medellín, Colombia.
Universidad de Antioquia · CO

Funding

Development of RNAi as Treatment for NeurodegenerationR01AG029802 · NIA · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI KOSIK, KENNETH STEPHEN · 2007 to 2011
$674k
NIA NIH HHS R01 AG029802NIA NIH HHS R01-AG029802-01
6 · The paper itself

Abstract

Inappropriate activation of cyclin-dependent kinase 5 (CDK5) resulting from proteolytic release of the activator fragment p25 from the membrane contributes to the formation of neurofibrillary tangles, β-amyloid (βA) aggregation, and chronic neurodegeneration. At 18 months of age, 3× Tg-AD mice were sacrificed after either 3 weeks (short term) or 1 year (long term) of CDK5 knockdown. In short-term-treated animals, CDK5 knockdown reversed βA aggregation in the hippocampi via inhibitory phosphorylation of glycogen synthase kinase 3β Ser9 and activation of phosphatase PP2A. In long-term-treated animals, CDK5 knockdown induced a persistent reduction in CDK5 and prevented βA aggregation, but the effect on amyloid precursor protein processing was reduced, suggesting that yearly booster therapy would be required. These findings further validate CDK5 as a target for preventing or blocking amyloidosis in older transgenic mice.

Indexed as

Amyloid beta-PeptidesAnimalsCyclin-Dependent Kinase 5Gene TargetingGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaMiceMice, TransgenicPhosphoric Monoester HydrolasesProtein Aggregation, PathologicalAmyloid beta-PeptidesCdk5 protein, mouseCyclin-Dependent Kinase 5Glycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGsk3b protein, mousePhosphoric Monoester HydrolasesAlzheimer's diseaseCDK5 RNAiGSK3β Ser9PP2Aβ-amyloid plaques

Identifiers

PMID25711385
PMCPMC4478163
OpenAlexW1550794020

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.